← All trials
NCT05952505
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Jul 19, 2023
- Last posted
- Jul 19, 2023
- Enrollment
- 540
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaReponsible party - principal investigator
- Government of ChinaStudy director
- China National Biotec Group Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.